OverviewSuggest Edit

Tempus Labs is a genomics and data-analytics company. It works with doctors and patients to use genomic data to more effectively choose treatment options based on outcomes from other patients.
TypePrivate
Founded2015
HQChicago, IL, US
Websitetempus.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Jun 2021)1,313(+3%)
Job Openings215
Cybersecurity ratingBMore

Key People/Management at Tempus

Eric Lefkofsky

Eric Lefkofsky

Founder & CEO
Shane Colley

Shane Colley

Chief Technology Officer
Joel Dudley

Joel Dudley

Chief Scientific Officer
Colette Freeman

Colette Freeman

Chief People Officer
Ryan Fukushima

Ryan Fukushima

Chief Operating Officer
Kim Blackwell

Kim Blackwell

Chief Medical Officer
Show more

Tempus Office Locations

Tempus has an office in Chicago
Chicago, IL, US (HQ)
600 W Chicago Ave #775
Show all (1)

Tempus Financials and Metrics

Summary Metrics

Founding Date

2015

Tempus total Funding

$620 m

Tempus latest funding size

$100 m

Time since last funding

a year ago

Tempus investors

Tempus's latest funding round in March 2020 was reported to be $100 m. In total, Tempus has raised $620 m. Tempus's latest valuation is reported to be $5 b.
View all funding rounds

Tempus Revenue

Market valuation

5.0b
Show all financial metrics

Tempus Operating Metrics

May, 2020

Product Categories

5

Samples Processed per Year (Infectious Diseases)

1 m

Trademarks

14
Show all operating metrics

Tempus Acquisitions / Subsidiaries

Company NameDateDeal Size
AKESOgenDecember 11, 2019

Tempus Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Tempus Online and Social Media Presence

Embed Graph

Tempus Company Culture

  • CEO Rating

    A+

    90/100

Learn more on Comparably

Tempus News and Updates

Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities

Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates Tempus’ platform will be used to further evaluate the DNA damage response pathway of Zentalis’ WEE1 inhibitor, ZN-c3, and potential future candidates

Tempus Resource by ProSymmetry Now Available on Carahsoft SEWP V and NASPO Contracts

Powerful Resource Management Solutions Now Available to Government Agencies Powerful Resource Management Solutions Now Available to Government Agencies

NeoGenomics and Tempus Join the Access to Comprehensive Genomic Profiling Coalition

Washington, February 2, 2021/ / -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of NeoGenomics, Inc.read more

PNC to buy payment gateway provider Tempus Technologies

PNC Bank N.A. today announced it has reached a definitive agreement to acquire Tempus Technologies, Inc., a leading payment gateway provider that delivers secure and innovative payment-processing solutions for businesses of all sizes.

Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-driven Precision Medicine to Accelerate Clinical Development of HMBD-001 In HER3 Driven Cancers

SINGAPORE, Dec. 14, 2020 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to...

EXCLUSIVE: Billionaire Eric Lefkofsky’s Tempus Raises $200 Million To Bring Personalized Medicine To New Diseases

The Groupon cofounder’s precision medicine company, which uses AI-based diagnostics, has broadened its focus to infectious disease and cardiology in addition to cancer.
Show more

Tempus Blogs

Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 – 8. “These high impact ASCO presentations from Tempus collaborato…

Tempus: 2021 CNBC Disruptor 50

Among the many market revelations to arise from the pandemic, one of the most obvious is that the health-care sector remains, in many ways, under-invested. While Covid highlighted a former No. 1 Disruptor whose technology bet was prescient, mRNA vaccine maker Moderna, Warren Buffett’s references to …

Tempus wins breakthrough status for AI-based tool to detect atrial fibrillation

By Meg Bryant March 24, 2021 The U.S. FDA has granted breakthrough device designation to Tempus Inc. for its ECG Analysis Platform. Developed in collaboration with Geisinger, the artificial intelligence (AI)-powered platform helps clinicians identify patients at increased risk of developing atrial f…

Tempus unveils prototype cube that talks back to oncologists

Tempus, a Chicago-based health technology company, wants oncologists to talk to the cube. The cube, in this case, is a device called Tempus One that doctors will be able to put in their lab coat pockets and bring with them as they round at hospitals, asking questions about their patients, the geneti…

Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing

Nature Genetics in Medicine, Tempus-authored — 2021 Update: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG) View the full publication here. Authors: David T. Miller, Kristy Lee, Adam S. Gordon, Laura M. Amendola, Kathy Adelman, Sherri J. Bale, Wendy K. Chung, Micha…

Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First-line Use

ASCO Annual Meeting 2021, Tempus-authored — Background: A growing number of genomic alterations inform treatment of advanced/metastatic colorectal cancer (mCRC). However, use of comprehensive genomic profiling (CGP) is limited in the first-line (1L) setting. Based on the Tempus xT next-generation se…
Show more

Tempus Frequently Asked Questions

  • When was Tempus founded?

    Tempus was founded in 2015.

  • Who are Tempus key executives?

    Tempus's key executives are Eric Lefkofsky, Shane Colley and Joel Dudley.

  • How many employees does Tempus have?

    Tempus has 1,313 employees.

  • Who are Tempus competitors?

    Competitors of Tempus include PathAI, Prognos Health and Genomic Health.

  • Where is Tempus headquarters?

    Tempus headquarters is located at 600 W Chicago Ave #775, Chicago.

  • Where are Tempus offices?

    Tempus has an office in Chicago.

  • How many offices does Tempus have?

    Tempus has 1 office.